ArticleCommunications biology2025
LAPTM5 exacerbates STING-mediated inflammation induced by LL-37 through stabilizing STING in rosacea.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Individual and Combined Cytotoxic Effects of Zearalenone and Zearalenone-14-Glucoside in Porcine Intestinal Epithelial Cells.Veterinary sciences · 2026Article
- Systemic Inflammatory and Oxidative-Metabolic Alterations in Rosacea: A Cross-Sectional Case-Control Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Rosacea is a chronic inflammatory skin disorder linked to the antimicrobial peptide LL-37 and immune cells. STING, a key DNA-sensing adaptor, initiates innate immune responses, with excessive activation contributing to inflammation. This study investigates LAPTM5, a STING-interacting protein, and its role in rosacea. We observe elevated nuclear DNA fragmentation within the dermal lesions of rosacea patients and LL-37-induced rosacea-like mice. LAPTM5 and STING levels are upregulated in macrophages within rosacea lesions and LL-37-induced models, along with STING hyperactivation. LAPTM5 knockdown in macrophages reduces STING protein levels, signaling, and inflammatory responses under DMXAA and HT-DNA stimulation. LAPTM5 associates with STING and represses its K48- and K63-linked polyubiquitination, preventing proteasomal and lysosomal degradation, thereby maintaining STING stability at homeostasis and after activation. Both STING antagonist H-151 and LAPTM5 knockdown alleviate LL-37-induced rosacea-like phenotypes. These findings highlight LAPTM5 as a STING stabilizer, aggravating STING-driven inflammation in rosacea, offering insights for potential treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.